Avidicure Funding Round

4/24/2025

Venture Equity

$50,000,000

Seed

Avidicure's fully owned proprietary platform leverages decades of antibody engineering and in silico protein design capabilities, and immunology expertise. Through the AVC-Booster plug-and-play functionality, multiple products can be developed. Avidicure's lead product, AVC-S-101, is a TROP2-targeting booster that is being developed for non-small cell lung cancer and multiple other indications.

Private & Independent

Biopharmaceutical

De Limes 7
Oegstgeest, 2342 DH
NL

Undisclosed

Avidicure is pioneering an entirely new dual agonistic, multifunctional and avidity engineered antibody modality, "AVC-Boosters", designed to safely deliver targeted and potent monotherapy, with broad applicability in oncology. AVC-Boosters unlock strong and orchestrated immunological responses, harnessing the full power of both the innate and adaptive immune system. The AVC-Booster design surpasses the best qualities of first-generation antibodies, checkpoint inhibitors, T-cell engagers and ADCs. The Company is based in the Netherlands and supported by a syndicate of top-tier investors led by EQT-Life Sciences, and with BioGeneration Ventures as founding investor.